Connect to other sites within the UBM Medica Network
In Development in Diabetes: 4 Amazing Technologies
What’s around the corner? Take a peek at 4 technologies in progress aimed at improving diabetes management.
GLP-1: Used Only as Needed
The ADA recommends GLP-1 agonists as second-line therapy against type 2 diabetes. What makes this class unique in its impact on hyperglycemia?
Metabolic Disease Research Roundup from AACE 2015
Metabolic issues are a large part of type 2 diabetes (T2DM) and particularly lipid disorders.
Incretin Therapy Side Effects Linked to Age, No Metformin Use
GI side effects compel many patients to stop GLP-1 agonist therapy. A new study identifies important risk factors to consider before prescribing.
GLP-1 Agonist Fails to Improve Coronary Flow Reserve in New Study
Incretin-based therapies have shown beneficial effects on the cardiovascular system, providing impetus for this recent study.
SGLT2 Inhibitors: Check Your A1c and BPs
Try this mid-week Q&A on 2 essential properties of the sodium glucose cotransporter 2 (SGLT2) inhibitors.
Dapagliflozin Plus Exenatide: Better Weight Loss Together?
What do you get when you combine an SGLT2 inhibitor and a GLP-1 receptor agonist into therapy for 1 diabetes patient?
Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.
By clicking Accept, you agree to become a member of the UBM Medica Community.